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Abstract
Background: Efficacy of statins has been extensively studied, with much less information reported on their
unintended effects. Evidence from randomized controlled trials (RCTs) on unintended effects is often insufficient to
support hypotheses generated from observational studies. We aimed to systematically assess unintended effects of
statins from observational studies in general populations with comparison of the findings where possible with
those derived from randomized trials.
Methods: Medline (1998 to January 2012, week 3) and Embase (1998 to 2012, week 6) were searched using the
standard BMJ Cohort studies filter. The search was supplemented with reference lists of all identified studies and
contact with experts in the field. We included prospective studies with a sample size larger than 1,000 participants,
case control (of any size) and routine health service linkage studies of over at least one year duration. Studies in
subgroups of patients or follow-up of patient case series were excluded, as well as hospital-based cohort studies.
Results: Ninety studies were identified, reporting on 48 different unintended effects. Statins were associated with
lower risks of dementia and cognitive impairment, venous thrombo-embolism, fractures and pneumonia, but these
findings were attenuated in analyses restricted to higher quality studies (respectively: OR 0.74 (95% CI 0.62 to 0.87);
OR 0.92 (95% CI 0.81 to 1.03); OR 0.97 (95% CI 0.88 to 1.05); OR 0.92 (95% CI 0.83 to 1.02)); and marked heterogeneity of
effects across studies remained. Statin use was not related to any increased risk of depression, common eye diseases,
renal disorders or arthritis. There was evidence of an increased risk of myopathy, raised liver enzymes and diabetes
(respectively: OR 2.63 (95% CI 1.50 to 4.61); OR 1.54 (95% CI 1.47 to 1.62); OR 1.31 (95% CI 0.99 to 1.73)).
Conclusions: Our systematic review and meta-analyses indicate that high quality observational data can provide
relevant evidence on unintended effects of statins to add to the evidence from RCTs. The absolute excess risk of
the observed harmful unintended effects of statins is very small compared to the beneficial effects of statins on
major cardiovascular events.
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Background
Randomized controlled trials (RCTs) of statins have
demonstrated their efficacy in preventing cardiovascular
diseases (CVD) but much less information has been
reported on their unintended effects [1-6]. In RCTs not
all harmful effects can be easily anticipated, but even if
measured, their reporting is inadequate [7]. Under-
reporting of unintended effects may affect the inter-
pretation of the net clinical benefit, particularly among
people at low cardiovascular risk.
The Cholesterol Treatment Trialists’ (CTT) collaboration,
an individual patient data overview of statin trials, has
provided strong evidence of benefit across all risk cat-
egories from secondary prevention to primary preven-
tion [8-11]. The CTT have confirmed an increased risk
of myopathies (including rhabdomyolysis) and found
no evidence of any increased risk of cancers [10,11].
Two recent meta-analyses of randomized trials have
suggested that statins might be associated with a 9%
increased relative risk of type 2 diabetes [12,13]. This
led to new safety alerts from both the USA Food and Drugs
Administration and the UK Medicines and Health-products
Regulatory Agency (MHRA) [14,15]. Statin-induced liver
dysfunction also occurs, but its incidence in the general
population, in contrast to trials, is not well defined.
Since the start of widespread use of statins in clinical
practice, numerous observational studies in North America
and Europe have provided contradictory results on the
effect of statins on a wide range of unintended effects
[16-21]. The lack of coherence is not surprising given
the inherent limitations in observational study designs,
but is a source of considerable anxiety for the general
public. Unfortunately, more robust evidence from RCTs
on such unintended effects is often insufficient to sup-
port or refute hypotheses generated from observational
studies, either because the relevant data were not collected
or not reported [22-27].
Although potential biases and confounding have to be
considered, population-based observational studies are more
likely to include a broad representation of the population
typically treated with statins. For these reasons, our objective
was to systematically assess unintended effects of statins
(with the exception of cancers) from observational studies
in the general population.
Methods
Criteria for inclusion of studies
This review focused on observational studies of any
unintended effects in general populations taking statins,
compared with non-users. We included prospective studies
with sample sizes larger than 1,000 participants, case
control studies (of any size) and routine health service
linkage studies of over at least one-year duration. Studies in
subgroups of patients (for example, patients with familial
hypercholesterolemia) or follow-up of patient case series
were excluded, as well as hospital-based cohort studies
(that is, cohort studies where the participants were se-
lected among patients admitted to a certain hospital).
Studies assessing lipid lowering drugs were included
only if separate data on statins were presented, or if the
study reported that statins accounted for the majority of
the lipid lowering drugs used.
For purposes of this review, an unintended effect was
any observational outcome reported (with the exception
of cancers as there are no longer any serious concerns
about excess cancer risk associated with statin use [11,28]),
either favorable or untoward. Efficacy endpoints of re-
duction in low-density lipoprotein (LDL) cholesterol
and total cholesterol were not considered but observational
assessments of cardiovascular endpoints were made to test
the validity of the approach.
Search strategy
We searched Medline (1998 to January 2012, week 3)
and Embase (1998 to 2012, week 6), using the stand-
ard BMJ Cohort studies filter [29]. The search was
limited to human studies, with no language restrictions
(see Additional file 1: Text S1 for search strategy). Our
search strategy aimed to detect observational studies that
were concerned with statins used for treatment of cardio-
vascular diseases. We did not attempt to search with terms
related to unintended consequences as specific difficulties
arise when ‘unintended effect’ terms are added to a search
strategy, because they are poorly reported, inadequately
indexed, inconsistently described and can be new or un-
expected at the time of searching [30]. Since no search
filter seemed to have high sensitivity and specificity in
both Medline and Embase databases [30], we supple-
mented our search with reference lists of all identified
studies (including reviews), and contacted experts in the
field asking for additional relevant articles.
Study selection and data extraction
One author (AFM) screened all titles and abstracts for
studies that could potentially meet the inclusion criteria
(Additional file 1: Text S2). Full articles were retrieved
for further detailed assessment by the same reviewer,
who then extracted onto a predesigned form information
on study design, sample size, study location and duration,
drug use and definition of exposure to statins, characteris-
tics of participants, relevant outcomes and effect estimates,
and degree of adjustment.
Two authors (FT and AA) checked a random sample
of 10% of the titles and the numbers extracted. This ap-
proach aimed to assess the magnitude of the discrepancies,
which might then lead to a decision to double-check all
articles. Since no discrepancies were identified, no further
duplicate checking was conducted. We also contacted 71
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authors to request additional information, ask for un-
published studies or clarify any uncertainty; 38 of them
provided additional information.
Assessment of risk of bias
The risk of bias in observational studies was assessed
using Newcastle-Ottawa Quality Assessment Scale (NOS)
(Additional file 1: Text S3) according to the procedures
recommended in the Cochrane Handbook of Systematic
Reviews [31]. One author (AFM) assessed the methodo-
logical quality of all the selected studies.
The NOS includes a ‘star system’ in which a study is
judged on three domains: representativeness of study group
selection (four items); comparability of groups (two items);
and ascertainment of either the exposure or outcome (three
items). When any item of NOS (for example, adequacy of
follow-up period) was not reported, a zero score was allo-
cated. Studies score one star for each area addressed, with
scores between 0 and 9 (the highest level of quality).
Data analysis
All meta-analyses used random effects models. For binary
outcomes, we assumed interchangeability of odds ratio
(OR), relative risk (RR) or hazard ratio (HR). Since the
majority of unintended effects of statins are fairly rare,
these measures will be similar [32]. Sensitivity analyses
were carried out according to study design to explore
the influence of different measures on the overall estimate
of effect. The natural logarithms of effect estimates with
95% confidence intervals were pooled across studies using
DerSimonian and Laird random-effects methods. If more
than one effect estimate was reported, the one derived
from the most adjusted model and with the longest
follow-up was used. Where estimates for a study were
provided for men and women, these were pooled into a
single estimate.
For continuous outcomes reported in different units,
we used the adjusted mean change from baseline to follow-
up, for exposed and unexposed, to obtain the standardized
mean difference (SMD). Analysis was conducted using the
metan command in Stata software (version 12.0 by Stata
Press, 4905 Lakeway Drive, College Station, Texas).
Heterogeneity
Because this review included only observational studies,
a greater level of heterogeneity was expected. We used
I2 statistic to assess between-study heterogeneity. Sen-
sitivity analyses were undertaken to explore the influ-
ence of different variables on the overall estimate of
effect and as potential sources of heterogeneity: study
design (cohort versus case-control studies), quality of
the study (higher quality for NOS ≥8 vs. NOS <8) and
sample size (within three categories: ≤100,000, 100,000
to 1 million, >1 million).
We undertook this systematic review and meta-analysis
according to PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) and MOOSE
(Meta-analysis of Observational Studies in Epidemiology)
guidelines during all stages of design, implementation and
reporting (see Additional file 1: Text S4 and Additional
file 1: Text S5 checklists). No original protocol for the
review was produced.
Results
Figure 1 summarizes the study selection process (see
Additional file 1: Text S2 for studies references). Additional
file 1: Table S1 summarizes the characteristics of the 86
articles included, regarding study design, dataset, study
population, sample size, follow-up duration and statin
type. The analysis comprised 90 studies, 43 cohort studies
and 47 case-control studies [17-20,33-114]. Only 6% of the
studies were conducted outside Europe (51%) or North
America (43%). The mean age of participants ranged from
47.0 to 81.2 years and among the 21 studies that reported
data on ethnicity, the most commonly investigated ethnic
group was Caucasians (75%).
Forty-eight potential unintended effects of statins were
identified, that is, described in at least one study. Definition
of exposure to statins was assessed in numerous ways and
included different types of statins. In 58 studies, exposure
to statins was defined by at least one prescription or self-
reported use during the study period.
A summary of the rating of risk of bias according to NOS
is presented in Figure 2. The overall quality of the studies
was high (mean score 7.1 out of a total possible of nine).
All but six studies received six to nine “stars” in the NOS.
The mean value of “assigned stars” was 7.4 (range 5 to 9)
in the cohort studies and 6.8 (range 3 to 8) in the case
control studies.
Meta-analysis
The summary effect estimates of each study were pooled to
give a total estimate of risk for each outcome (Figure 3). Ef-
fect sizes from meta-analyses of RCTs or single large RCTs
were also plotted when available for comparative purposes.
Neurologic and psychological effects
Thirteen studies with 2,762,899 participants examined the
association between use of statins and incidence of any
combination of the dichotomous outcomes: dementia, cog-
nitive impairment without dementia (CIND) or Alzheimer’s
disease (AD). An odds ratio of 0.70 (95% CI 0.59 to 0.83)
was observed for those participants exposed to statins;
but the higher quality studies showed an attenuated
effect (OR 0.74, 95% CI 0.62 to 0.87) compared with
the lower quality studies (OR 0.53, 95% CI 0.37 to 0.92)
(Additional file 1: Figure S1-A). Marked between-study
heterogeneity as indicated by high I2 values was observed
Macedo et al. BMC Medicine 2014, 12:51 Page 3 of 13
http://www.biomedcentral.com/1741-7015/12/51
which was not explained by stratifying by study quality.
Similar association of statin use was observed when the
analysis was restricted to incident Alzheimer’s disease
(OR = 0.61; 95% CI 0.50 to 0.75), dementia (not Alzheimer’s)
(OR = 0.73; 95% CI 0.61 to 0.88) and for incident Parkinson’s
disease (OR = 0.84; 95% CI 0.74 to 0.95). One case control
study recruited prevalent cases of Parkinson’s disease and
observed a stronger risk reduction (OR= 0.37; 95% CI 0.19
to 0.72) [56]. This study was excluded from the pooled
analysis because it was responsible for significant het-
erogeneity between studies (I2 = 63.2% vs. I2 = 51.8%).
Improved cognitive test scores were observed in two
studies: standardized mean difference of 0.18 (95% CI
0.09 to 0.27) [19,101]. In a cohort study of 21 years,
statin treatment was related to better performance in
episodic memory and psychomotor speed tests (5 to 8%
relative differences) [96].
Figure 1 Flow chart for identifying eligible studies. The search strategy yielded 12,010 publications, of which 1,674 were duplicates and
10,230 references were not eligible based on abstract and title review. We systematically searched the reference lists of the remaining 110 eligible
articles and of 33 reviews, and contacted experts. Ninety-five additional studies were identified that were not captured with our initial search
strategy. Of this total, five references of short communications await classification because we were unable to contact the author or received no
answer regarding a possible publication. Full papers were obtained for 200 references. From these, 63 were excluded for not fulfilling inclusion
criteria. Of the identified 137 references, 51 assessed statin risk of cancer and were excluded from the present analysis; we focused on the
remaining 86 references.
Figure 2 Newcastle-Ottawa Quality Assessment: number of studies
by number of “stars” assigned, according to study design.
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Figure 3 Summary of results from random-effects meta-analyses for each outcome and estimates from Randomized Controlled Trials.
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Four studies (108,449 participants) reported on periph-
eral neuropathy and no strong evidence of increased risk
was observed (OR = 1.91; 95% CI 0.89 to 4.41, I2 = 73.9%,
random effects model) [33,39,48,49]. Studies of low
quality (NOS <8) showed a more pronounced association
(OR = 2.57; 95% CI 1.04 to 6.32) [33,48,49].
Four studies (735,143 participants) reported on depression
and suicidal behavior [17,70,94]. No evidence of increased
risk was seen for these endpoints (OR = 0.83; 95% CI 0.50
to 1.39) and this result was consistent across sub-groups.
Eye disorders
The outcomes comprised age-related macular degeneration
(AMD), cataract and glaucoma. No strong evidence of asso-
ciation was observed in the pooled analysis using random
effects model for any of these outcomes (Figure 3).
Venous thromboembolism (VTE)
Using a random effects model, a relative risk reduction of
VTE, which favored statin treatment by 26%, was observed
(OR = 0.74; 95% CI 0.61 to 0.89). There was marked
heterogeneity of effects across studies (I2 = 84.1%).
Analysis restricted to the four studies with higher qual-
ity (NOS ≥8), including 2,737,152 participants, showed
marked attenuation of the risk reduction (OR = 0.92;
95% CI 0.81 to -1.03).
Fractures
A relative risk reduction of fractures on statin treat-
ment by 22% was observed (OR = 0.78; 95% CI 0.68 to
0.89, I2 = 91.2%) but this was markedly attenuated
when analysis was restricted to the five higher quality
studies (OR = 0.97; 95% CI 0.88 to 1.05) and in the cohort
studies (OR = 0.85; 95% CI 0.72 to 1.00) and in the three
largest studies (OR = 0.98; 95% CI 0.95 to 1.02; I2 = 0.0%)
(Additional file 1: Figure S1-B).
Myopathy
A markedly increased risk of myopathy was observed
(OR = 2.63; 95% CI 1.50 to 4.61, I2 = 98.2%), which was
consistent in sub-groups by study design, quality and
size but the heterogeneity remained. In a single study,
statin treatment was related to an average reduction in grip
strength (kg) from baseline of 0.24 kg (men) to 0.52 kg
(women) [34]. No evidence of any increase in myopathy
in primary prevention RCTs was found (RR = 1.03, 95%
CI 0.97 to 1.09, I2 = 41%) [1]. CTT results demonstrated
an increased risk of myopathy conferred by statins, and
an observed excess of rhabdomyolysis of 1 (SE 1) per
10,000 in the 21 trials of standard statin regimens versus
control (14 vs. 9 cases) [9].
Incidence rates of events according to exposure and
outcome definition were examined (Table 1), and in
prospective studies ranged from 2.30 to 9.06 per 10,000
person-years, with an excess rate between 2.10 and 5.77 per
10,000 person-years. Two studies only reported data on ab-
solute risk of myopathy (26 and 11 per 10,000 participants),
corresponding to an estimated excess risk of 22 and 8
per 10,000 participants, respectively [55,94]. One study
presented what the authors called “prevalence rates” of
any myopathic event, in diabetic and nondiabetic sub-
jects, with rates of 242 and 268 per 10,000 person-years,
respectively [78].
Liver disorder and raised liver enzymes
The definition of hepatic disorders was ascertained by
medical codes for “acute liver disease” in the study by
Smeeth et al. [94], and by an ALT ≥120 IU/l among
patients without chronic liver disease in the study by
Hippisley-Cox et al. [55] Both studies observed an in-
creased risk of liver disorders. Smeeth et al. found an
increased risk of incident liver disease in the first year
after the index date (HR 1.51; 99% CI 1.19 to 1.91), but
little or no increased risk after this time (HR 1.11; 99% CI
0.98 to 1.24); and Hippisley-Cox et al. found an increased
risk of liver enzyme changes (HR = 1.54; 95% CI 1.47 to
1.62). Results were not pooled across the two definitions
of liver disorders. Incidence of liver disorders in these two
large prospective studies ranged from 44 to 120 per 10,000
participants, corresponding to an estimated excess risk of
16 and 50 per 10,000 participants, respectively (Table 1)
[55,94]. In two additional studies, both gallstones and
cholecystectomy events were less common in patients
treated with statins (Additional file 1: Figure S2).
Renal disorder
No evidence of increased risk of renal disorder was ob-
served (OR = 1.18; 95% CI 0.65 to 2.14, I2 = 99.2%). The
observed heterogeneity might be due to different outcome
definitions. The study by Hippisley-Cox et al. found an in-
creased risk of “acute renal failure” ascertained by medical
codes [55]; while the study by Sukhija et al. [100] found a
protective effect of statins on renal dysfunction. A moder-
ate rise in urinary albumin excretion (UAE) in statin users
(+12.1%) compared with non-users (+3.6%), which was
more pronounced with higher dose or duration of statin
treatment has been reported, but with no change in glom-
erular filtration rate (GFR) [35].
Type 2 diabetes
Overall, weak evidence of an increased risk of type 2
diabetes mellitus (T2DM) was observed (OR = 1.31; 95% CI
0.99 to 1.73, I2 = 72.1%). One cohort study (Women’s
Health Initiative) of higher quality and larger sample size
found stronger evidence of an increased risk of self-
reported T2DM (OR = 1.47; 95% CI 1.32 to 1.64) for the
groups of women who reported statin use at baseline and
three years later [41]. The cumulative incidence of T2DM
Macedo et al. BMC Medicine 2014, 12:51 Page 6 of 13
http://www.biomedcentral.com/1741-7015/12/51
after three years of statin treatment was 6.25%, corre-
sponding to an excess risk of 2.25% (Table 1). This excess
risk corresponds to a number needed to harm (NNH) of
44 patients (95% CI 35 to 60) for an additional case of dia-
betes over three years of statin treatment. Conversely, a
nested case-control study using data from the General
Practice Research Database (GPRD) found no association
between statin use and T2DM development (OR = 1.10;
95% CI 0.83 to 1.46) [59].
Rheumatoid arthritis and osteoarthritis
No increased risk of rheumatoid arthritis or osteoarthritis
was observed (OR = 1.00; 95% CI 0.77 to 1.30, I2 = 75.7%),
which was confirmed in the two cohort studies with
higher quality and sample size (OR = 1.00; 95% CI 0.93 to
1.08), while the two case control studies reported conflict-
ing results (Additional file 1: Figure S1-C).
One cohort study reported on the progression of
osteoarthritis and observed a protective effect of statins
(OR = 0.43; 95% CI 0.25 to 0.77) [38]. No association
between statin treatment and other outcomes with a
possible immune mechanism (psoriasis, multiple sclerosis
or systemic lupus erythematosus) was found (Additional
file 1: Figure S2).
Pneumonia
A risk reduction of pneumonia was observed (OR = 0.88;
95% CI 0.80 to 0.98, I2 = 61.7%), which was attenuated
in analysis restricted to the three cohort studies with
higher quality (NOS ≥8) (OR = 0.92; 95% CI 0.83 to 1.02)
(Additional file 1: Figure S1-C) [46,64,94]. Smeeth et al.
[94] and Fleming et al. [46] also found no association
between statin treatment and infection-related outcomes,
such as acute bronchitis, acute respiratory infections, other
respiratory tract infections (no pneumonia) or urinary tract
infections, (Additional file 1: Figure S2).
Other possible unintended effects
No evidence of excess risk of other possible unintended
effects that have been suggested was found (Additional
file 1: Figure S2). Expected risk reductions were observed
for stroke and myocardial infarction. Some unexpected
risk reductions were found. Current statin use was associ-
ated with a reduced risk of chronic obstructive pulmonary
Table 1 Incidence rate and excess risk attributable to statins for myopathy, hepatic disorder and diabetes
Author, year Incidence/10.000
person-years or %
(95% CI)
Excess risk/10.000
person-years or %
Exposure definition Outcome definition
Myopathy
Gaist et al. [50] 2.30 2.10 One prescription and additional
30 days supply
Medical codes for myopathic events
and validation by independent
blind review of medical records(1.20 to 4.40)
Hippisley-Cox et al. [55] 0.26% 0.22% First prescription after January 2002 Medical codes for moderate or serious
myopathic events (myopathy or
rhabdomyolysis or a CK ≥4X ULN)(0.24% to 0.28%)
McClure et al. [77] 9.06 5.77 One prescription during the
study period
Medical codes for myopathy and
CK ≥10X ULN
(n.r.)
Smeeth et al. [94] 0.11% 0.08% First prescription after January 1995 Medical codes for myositis or myolysis
(n.r.)
Hepatic disorder
Hippisley-Cox et al. [55] 1.20% 0.50% First prescription after January 2002 ALT ≥120 IU/l among patients without
chronic liver disease
(1.13% to 1.22%)
Smeeth et al. [94] 1.60% 0.30% First prescription after January 1995 Medical codes for acute liver disease
First year only 0.44% 0.16%
(n.r.)
Diabetes
Culver et al. [41] 6.25% 2.25% One prescription at the first screening
interview and three-year follow-up
Self-report of a new physician
diagnosis of treated diabetes
(5.71% to 6.84%)
Jick et al. [59] n.a. n.a. Two prescriptions one year before
index date
Medical code for first diagnosis of
diabetes plus more than two
prescriptions for a hypoglycaemic
agent or three records of diet
management
ALT, alanine transaminase; CK, creatine kinase; n.a., not applicable in a nested case control study; n.r., confidence intervals not reported; ULN, upper limit
of normal.
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disease (COPD) (OR = 0.45; 95% CI 0.25 to 0.80) in a sin-
gle study of only one-year duration in which the role of
smoking was unclear [88]. The other studies reporting
protective associations between statin use and low urinary
tract symptoms, subarachnoid hemorrhage and intra-
cerebral hemorrhage were all small with poor assigned
quality (NOS ≤6) [84,99,110].
Discussion
We found no increased risk of peripheral neuropathy,
depression, common eye diseases, renal disorders or
arthritis associated with taking statins. Studies of higher
quality did not show previously reported protective ef-
fects of statins on fractures, venous thrombo-embolism
or pneumonia. Lower odds of dementia and cognitive
impairment were associated with statin use but were at-
tenuated in higher quality studies indicating that they
may not be robust. There was evidence of an increase in
myopathy, raised liver enzymes and diabetes. The pooled
observational findings were heterogeneous which might
reflect differences in study quality, the populations stud-
ied and how statin exposure and effects were measured.
Observational studies of effects of drugs are beset with
problems of ‘confounding by indication’ which results in
people on treatment often having worse outcomes than
those not on treatment simply because they are sicker.
In the studies reviewed here, investigators attempted to
obtain comparable groups by a range of methods including
simple matching, controlling for potential confounders and
propensity score matching. None of these methods are
as efficient as randomization in controlling for selection
bias and confounding but for rare outcomes and to study
typical patients using drugs in the general population,
observational studies provide the only means of making
assessments. Moreover, population-based observational
studies provide reliable estimates of the incidence of effects
experienced in the general population, important in evalu-
ating the public health impact of an intervention, as this
usually cannot be done reliably using randomized trial data
(because of limited power and differences between trial
samples and general populations).
Comparison of results with randomized trials
For unintended effects that had been reported in RCTs,
the effect estimate derived from observational studies was
compared with RCT findings to determine the extent to
which observational studies were capable of obtaining
robust findings. This approach has been used previously
[94]; and a recent study found no difference in the risk
estimate of adverse effects of interventions derived from
meta-analyses of RCTs and meta-analyses of observational
studies, suggesting that these may be estimated reliably
from observational data [115]. For this comparison we used
results from published data from the CTT collaboration,
systematic reviews from the Cochrane collaboration or
recent systematic reviews on specific unintended effects
that superseded either of these sources. Pooled or single
RCT estimates are presented below the observational
pooled estimates for the higher quality studies and indicate
that in the RCT and observational findings were broadly
similar (Figure 3), although RCT estimates tended to be
more conservative. Consistency between observational
and RCT findings suggests that confounding by indica-
tion is unlikely to invalidate the observational results,
particularly for estimates obtained from large, better quality
observational studies.
Evidence from recent systematic reviews and meta-
analyses of randomized trials showed no differences in
risk of psychological outcomes [116], fractures [117], acute
renal failure [118], arthritis [1] or venous thromboembol-
ism [119]. A recent meta-analysis of randomized trials and
prospective cohort studies concluded that long-term data
may support a beneficial effect of statins in the prevention
of dementia [120] and another review of statins and cogni-
tive impairment found no strong evidence of an association
with Alzheimer disease or cognitive function [121].
A recently published meta-analysis of observational
studies also found a similar reduction in the likelihood
of pneumonia associated with statin use [122], in line
with randomized findings from the Justification for the
Use of Statins in Primary Prevention: an Intervention
Trial Evaluating Rosuvastatin (JUPITER) trial [123]. Statin
use may be a surrogate marker for better health which may
confound the observed association with pneumonia [124].
RCTs in both primary and secondary prevention found
an increased risk of T2DM (OR 1.18; 95% CI 1.01 to
1.39 and OR = 1.09; 95% CI 1.02 to 1.17) [1,12]. This as-
sociation appears to be higher with intensive-dose statin
therapy and among elderly subjects [125], and is strongly
associated with baseline fasting blood glucose and co-
existing CVD risk factors, suggesting that statins raise
blood glucose by a small amount, moving people from
below to above the diagnostic threshold [126]. In a re-
cent observational cohort study, atorvastatin and sim-
vastatin compared with pravastatin were associated
with an increased risk of new onset diabetes [127]. In a
new analysis of the JUPITER primary prevention trial,
the cardiovascular and mortality benefits of statin therapy
exceeded the risk of developing diabetes even in people
at high risk of developing diabetes [128]. Although the
mechanism underlying the increase in new onset T2DM
in patients treated with statins is unknown, it is possible
that statins interfere with insulin signaling, leading to
hyperinsulinemia, insulin resistance, metabolic syndrome,
pre-diabetes and diabetes [129-131].
The apparent protective effect of statin use on cognitive
function was linked with ApoE4 genotype in one study
among individuals <80 years [68]. Further research is
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needed to assess the possible interaction of statin use
and ApoE genotype on risk of AD or dementia.
Our analysis gave higher estimates than RCTs for
myopathy which may reflect differences in the diagnos-
tic criteria used and the populations studied. Myopathy
is more likely to occur with higher doses of statins and
in situations that raise statin blood levels, including ad-
vanced age, frailty, deterioration of renal function and
the presence of interacting drugs [132], all common
exclusions for RCTs. A blinded, controlled trial among
healthy statin-naïve people showed that high-dose atorva-
statin for six months had no effect on muscle strength or
exercise performance but confirmed that statins increase
muscle complaints and increased average creatine kinase,
suggesting that statins produce mild muscle injury even
among asymptomatic subjects [133]. An observational
study using military personnel records found that muscu-
loskeletal conditions, arthropathies, injuries and pain were
more common among statin users than among propensity
score-matched nonusers [134].
No increased risk of renal disease attributable to statin
treatment was found in our review. Recent systematic
reviews of trials have demonstrated lower mortality and
cardiovascular events in persons with early stages of
chronic kidney disease (CKD) on statins, but little or no
effect in persons receiving dialysis, and uncertain effects
in kidney transplant recipients [135,136].
We found an increased risk of liver disorders, although
outcome definition was heterogeneous across studies.
With the exception of statin-induced transaminase ele-
vation, large statins trials have not shown an increase in
the incidence of liver diseases. In a systematic review of
21 randomized trials, elevated transaminases occurred
with an excess rate of 7 per 10,000 person-years but liver
disease was rare (0.05 per 10,000 person-years) [137].
This was confirmed in a larger network meta-analysis
[138]. Routine monitoring of liver function after starting
a statin is no longer recommended [14].
Limitations and strengths
One major strength of our systematic review is the in-
clusion of a large number of observational studies in
general populations and a wide range of potential un-
intended effects of statins. Therefore, our analysis is
more likely to include a broad representation of the
population at-risk, and may reflect better the nature
and frequency of unintended effects experienced in
clinical practice.
Despite the many positive aspects, observational re-
search is prone to bias and confounding. The results
from the studies included in this meta-analysis could
be influenced by a “healthy-user” effect and closer
monitoring. We explored the robustness of our results
across three dimensions: study design, sample size and
quality of the studies but heterogeneity of the pooled
observational findings could not be explained by them,
and may reflect the different populations studied, how
the statin exposure was measured or different outcome
definitions. It was not possible to assess the consistency of
outcome definitions between studies which is an inherent
limitation of systematic reviews based on published data.
We also recognize the limitation of having a single re-
viewer assessing all data extraction and validity; although
no discrepancies were identified in a random sample of
10% of the titles and the numbers extracted. Publication
bias is a particular threat to the validity of meta-analysis of
observational studies. Although we contacted authors
asking for unpublished studies, publication bias is pos-
sible since observational studies with significant out-
comes are more likely to be published and, therefore,
over-represented in our meta-analysis. The pooled ef-
fect sizes may potentially be exaggerated by this bias.
A further limitation is the difficulty in keeping this
review up to date given the high level of publication on
statins. In recognition of this we conducted a rapid up-
date search of Medline (January 2012 to February 2014,
terms: statins, humans, core medical journals, 141 hits) and
have incorporated substantive new findings in relevant
sections of our discussion.
Some unintended effects (for example, ventricular
arrhythmia, intracerebral hemorrhage) were not covered in
this meta-analysis as they were not reported in population-
based studies, but from case reports and clinical case series
which provide weaker evidence of causal association. A
recent meta-analysis including RCTs and observational
studies (mainly secondary analysis of RCTs and small
studies in subgroups of patients with atrial fribrillation
or acute ischemic stroke) found no association between
statin exposure and intracerebral hemorrhage, consist-
ent across study designs [139].
Implications for clinical practice
Statins are widely used in clinical practice and their ef-
ficacy for secondary prevention of CVD is well founded,
but their expanding use in primary prevention in low-risk
individuals has to be balanced against the risk of ‘over-
medicating’ the general population [140]. This assumes
particular importance since findings from a recent co-
hort of 3.8 million general population patients of UK
Clinical Practice Research Datalink (CPRD) showed
substantive overuse of statins in low CVD risk and
underuse in high CVD risk [141]. Given that several
trials are currently evaluating the effects of a polypill
on risk factor levels, the use of statins is likely to in-
crease to a much wider section of the population
(whether by age or by cut-off on absolute risk) [142].
Thus, accurate evidence on the potential unintended
effects of statins is of public health relevance.
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The observed unintended effects, most importantly
myopathy and elevated liver enzymes, are rare and
more likely to occur with higher doses of statins. The
possible increased risk of developing T2DM has resulted
in surveillance recommendations.
Implications for future research
Reporting of unintended effects in RCTs is not done
consistently and failure to report such findings introduces
bias into evaluations of the benefits and harms of treat-
ments. Considerable adverse event data are collected in
most RCTs but are not readily available to include in sys-
tematic reviews. Future research in this area will need to
engage with pharmaceutical companies to obtain relevant
data to enable unbiased assessments of the true levels of
common unintended effects of statins.
Conclusion
Our systematic review and meta-analyses indicate that
high quality observational data can provide reliable and
relevant evidence on unintended effects of statins to
add to the evidence from RCTs for health care guidance.
Comparisons of the observational findings with RCTs,
where possible, showed similar estimates, indicating that
our approach is capable of making plausible inferences on
unintended effects. The absolute excess risk of the ob-
served harmful unintended effects of the statin class of
drugs is very small compared to the beneficial effects of
statins on major cardiovascular events.
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